Literature DB >> 8956323

Pharmaceutical approach to somatic gene therapy.

F D Ledley1.   

Abstract

The pharmaceutical approach to somatic gene therapy is based on consideration of a gene as a chemical entity with specific physical, chemical and colloidal properties. The genes that are required for gene therapy are large molecules (> 1 x 10(6) Daltons, > 100 nm diameter) with a net negative charge that prevents diffusion through biological barriers such as an intact endothelium, the plasma membrane or the nuclear membrane. New methods for gene therapy are based on increasing knowledge of the pathways by which DNA may be internalized into cells and traffic to the nucleus, pharmaceutical experience with particulate drug delivery systems, and the ability to control gene expression with recombined genetic elements. This article reviews two themes in the development of gene therapies: first, the current approaches involving the administration of cells, viruses and plasmid DNA; second, the emerging pharmaceutical approach to gene therapy based on the pharmaceutical characteristics of DNA itself and methods for advanced drug delivery.

Mesh:

Substances:

Year:  1996        PMID: 8956323     DOI: 10.1023/a:1016420102549

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  210 in total

1.  A novel mechanism for achieving transgene persistence in vivo after somatic gene transfer into hepatocytes.

Authors:  J M Wilson; M Grossman; J A Cabrera; C H Wu; G Y Wu
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

2.  Cyclic amphipathic peptide-DNA complexes mediate high-efficiency transfection of adherent mammalian cells.

Authors:  J Y Legendre; F C Szoka
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

3.  Gene transfer into primary and established mammalian cell lines with lipopolyamine-coated DNA.

Authors:  J P Loeffler; J P Behr
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

4.  Targeted gene transfer into hepatoma cells with lipopolyamine-condensed DNA particles presenting galactose ligands: a stage toward artificial viruses.

Authors:  J S Remy; A Kichler; V Mordvinov; F Schuber; J P Behr
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

5.  Cellular and molecular barriers to gene transfer by a cationic lipid.

Authors:  J Zabner; A J Fasbender; T Moninger; K A Poellinger; M J Welsh
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

6.  Generation of novel, biologically active Harvey sarcoma viruses via apparent illegitimate recombination.

Authors:  M P Goldfarb; R A Weinberg
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

7.  Cationic liposome-mediated intravenous gene delivery.

Authors:  Y Liu; D Liggitt; W Zhong; G Tu; K Gaensler; R Debs
Journal:  J Biol Chem       Date:  1995-10-20       Impact factor: 5.157

8.  A novel cationic liposome reagent for efficient transfection of mammalian cells.

Authors:  X Gao; L Huang
Journal:  Biochem Biophys Res Commun       Date:  1991-08-30       Impact factor: 3.575

9.  Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle.

Authors:  E Wagner; C Plank; K Zatloukal; M Cotten; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

10.  Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells.

Authors:  P Pinnaduwage; L Schmitt; L Huang
Journal:  Biochim Biophys Acta       Date:  1989-10-02
View more
  18 in total

1.  Nuclear transport of oligonucleotides in HepG2-cells mediated by protamine sulfate and negatively charged liposomes.

Authors:  C Welz; W Neuhuber; H Schreier; M Metzler; R Repp; W Rascher; A Fahr
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

Review 2.  Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization.

Authors:  R J Mumper; H C Ledebur
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

3.  Multiple and time-scheduled in situ DNA delivery mediated by beta-cyclodextrin embedded in a polyelectrolyte multilayer.

Authors:  N Jessel; M Oulad-Abdelghani; F Meyer; P Lavalle; Y Haîkel; P Schaaf; J-C Voegel
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-30       Impact factor: 11.205

4.  Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability.

Authors:  P Erbacher; S Zou; T Bettinger; A M Steffan; J S Remy
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

Review 5.  Cationic lipid-based gene delivery systems: pharmaceutical perspectives.

Authors:  R I Mahato; A Rolland; E Tomlinson
Journal:  Pharm Res       Date:  1997-07       Impact factor: 4.200

6.  In vitro transfection of plasmid DNA by amine derivatives of gelatin accompanied with ultrasound irradiation.

Authors:  Hossein Hosseinkhani; Ternyoshi Aoyama; Shingo Yamamoto; Osamu Ogawa; Yasuhiko Tabata
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

7.  Tetrafluoroethane (HFC 134A) propellant-driven aerosols of proteins.

Authors:  A R Brown; D W George
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

8.  Suppression of the progress of disseminated pancreatic cancer cells by NK4 plasmid DNA released from cationized gelatin microspheres.

Authors:  Toshihiro Kushibiki; Kunio Matsumoto; Toshikazu Nakamura; Yasuhiko Tabata
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

9.  Surface polyethylene glycol enhances substrate-mediated gene delivery by nonspecifically immobilized complexes.

Authors:  Angela K Pannier; Julie A Wieland; Lonnie D Shea
Journal:  Acta Biomater       Date:  2007-09-01       Impact factor: 8.947

10.  Non-viral vector delivery from PEG-hyaluronic acid hydrogels.

Authors:  Julie A Wieland; Tiffany L Houchin-Ray; Lonnie D Shea
Journal:  J Control Release       Date:  2007-05-01       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.